Peptide Initiative

Peptide profile · Hormone Support

Leuprolide

A powerful GnRH agonist that helps manage hormone-sensitive conditions by controlling hormone production.

Strong human trialsFDA approved for this use
Approximately 2-6 hoursHalf-life (varies by route of administration)
~95%Bioavailability (subcutaneous injection)
1209.4Molecular weight, g/mol

Molecular formula

C59H84N16O12

CAS number
74381-53-6
PubChem
657181
Developed · 1985
TAP Pharmaceuticals Research Team, TAP Pharmaceuticals (Abbott Laboratories & Takeda joint venture)

Amino acid sequence

pyroGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt

Cancer ManagementEffectively reduces testosterone in men with prostate cancer

9.4

Endometriosis & Fibroid ReliefRelieves severe endometriosis pain and symptoms

9.0

Hormone ControlReversible hormone suppression with minimal long-term effects

8.7

Ratings out of 10.

1mg

Every documented dose level

PhaseDoseFrequencyRoute
Ongoing1 mgOnce dailySubcutaneous
Ongoing7.5 mgEvery monthIntramuscular
Ongoing22.5 mgEvery 3 monthsIntramuscular
Ongoing30-45 mgEvery 4-6 monthsIntramuscular
Build my protocolBuild my protocol opens your schedule and dose log to save, share and keep on your phone.

Best for managing advanced or metastatic prostate cancer & controlling severe endometriosis pain

Best for

  • Managing advanced or metastatic prostate cancer

    Leuprolide is particularly well-suited for individuals focused on managing advanced or metastatic prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

  • Controlling severe endometriosis pain

    Leuprolide is particularly well-suited for individuals focused on controlling severe endometriosis pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

  • Treating symptomatic uterine fibroids

    Leuprolide is particularly well-suited for individuals focused on treating symptomatic uterine fibroids. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

  • Delaying early puberty in children

    Leuprolide is particularly well-suited for individuals focused on delaying early puberty in children. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .

Consider alternatives if

Alternative approaches for hormone support supportConsult your healthcare provider for alternatives to Leuprolide based on your specific needs and medical history
Alternative hormone-supporting peptidesKisspeptin-10GonadorelinPT-141 (Bremelanotide)
Non-peptide hormone supportClomiphene citrateAnastrozoleLifestyle modifications (sleep, exercise)

Do not use if

  • Pregnancy or breastfeeding (teratogenic)
  • Undiagnosed vaginal bleeding
  • Active bone metastases with spinal cord compression (increased fracture risk)
  • Allergy to GnRH agonists or components
  • Severe cardiovascular disease with QT prolongation risk

Use with caution if

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about Leuprolide use
  • You have any chronic health conditions that require regular monitoring

Not sure?

Compare Leuprolide with similar peptides to find the best fit for your goals.

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

  • Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
  • Front of thighs—middle to upper portion of the outer leg
  • Back of upper arm—outer area (may need assistance from another person)

The Leuprolide injection guide covers reconstitution · step-by-step technique · storage · a sample daily schedule.

15 common side effects · 1 serious

Emergency signs first, then what this page and MedlinePlus say.

Leuprolide (Lupron) is an FDA-approved GnRH agonist with 35+ years of clinical safety data involving millions of patients in oncology and endocrinology.

The critical safety issue is the initial 5-7 day flare effect—temporary surge in FSH/LH causing symptom worsening before hormone suppression begins—particularly dangerous for prostate cancer patients (flare can cause urinary obstruction or spinal cord compression).

Bone density loss is a dose-dependent long-term risk in both men and women requiring monitoring. Injection site reactions, hot flushes, and initial hypogonadal symptoms are expected and typically transient.

Leuprolide safety is well-established through FDA registration trials, extensive post-marketing surveillance, and hundreds of published clinical studies spanning endometriosis, prostate cancer, precocious puberty, and breast cancer indications.

Long-term safety data from 10+ years of continuous therapy shows predictable hypogonadal effects with manageable metabolic consequences when monitored appropriately. Black box warnings exist for flare risk in certain prostate cancer scenarios and bone loss risk in extended use.


Common side effects · experienced by some users

Hot flashes (very common in men)

Hot flashes (very common in men)

Management
Consult your healthcare provider for guidance.

Decreased libido and erectile dysfunction

Decreased libido and erectile dysfunction

Management
Consult your healthcare provider for guidance.

Injection site pain or swelling

Injection site pain or swelling

Management
Consult your healthcare provider for guidance.

Nausea

Nausea

Management
Consult your healthcare provider for guidance.

Fatigue

Fatigue

Management
Consult your healthcare provider for guidance.

Mood changes or depression

Mood changes or depression

Management
Consult your healthcare provider for guidance.

Joint or muscle pain

Joint or muscle pain

Management
Consult your healthcare provider for guidance.

Headaches

Headaches

Management
Consult your healthcare provider for guidance.

Dizziness

Dizziness

Management
Consult your healthcare provider for guidance.

Thinning hair

Thinning hair

Management
Consult your healthcare provider for guidance.

Decreased bone density (osteoporosis with long-term use)

Decreased bone density (osteoporosis with long-term use)

Management
Consult your healthcare provider for guidance.

QT prolongation (rare but serious cardiac effect)

QT prolongation (rare but serious cardiac effect)

Management
Consult your healthcare provider for guidance.

Tumor flare (temporary worsening of cancer symptoms in first weeks)

Tumor flare (temporary worsening of cancer symptoms in first weeks)

Management
Consult your healthcare provider for guidance.

Severe allergic reactions

Severe allergic reactions

Management
Consult your healthcare provider for guidance.

Spinal cord compression risk in men with metastatic disease

Spinal cord compression risk in men with metastatic disease

Management
Consult your healthcare provider for guidance.

Serious side effects

Severe allergic reaction

In rare cases, Leuprolide may trigger a severe allergic reaction including difficulty breathing, facial swelling, or widespread rash. This requires immediate medical attention .

Management
STOP treatment immediately and seek emergency medical care. Do not restart without medical clearance. Report all allergic reactions to your healthcare provider.


Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with Leuprolide
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

Leuprolide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.


With other peptides

  • SafeAnti-androgens (like bicalutamide) for prostate cancer — May be used together under medical guidance.
  • SafeNSAIDs (like naproxen) for endometriosis pain — May be used together under medical guidance.
  • SafeBone-protecting agents (bisphosphonates) for long-term use — May be used together under medical guidance.

With medications

  • CautionOther GnRH agonists (would cause overdosing) — Use with caution—discuss with your healthcare provider.
  • CautionCertain medications that prolong QT interval — Use with caution—discuss with your healthcare provider.
  • CautionAvoid if taking medications that significantly interact with testosterone suppression — Use with caution—discuss with your healthcare provider.

With supplements

  • SafeMultivitamins — Generally safe to take alongside Leuprolide. Space doses apart if taking oral formulations to ensure optimal absorption.
  • SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Strong human trials · first signs initial_response

Evidence level

Strong human trials

(Phase 3 or FDA approved)

100/100

Regulatory status

FDA approved for this use

Onset of effects

Moderate

(1-2 weeks)


How it works

Leuprolide works by pretending to be your brain's natural GnRH hormone, but in a way that confuses your pituitary gland.

For the first week, it actually stimulates hormone production, but then your body gets exhausted and shuts down the whole system. This stops testosterone in men and estrogen in women—exactly what you need for hormone-sensitive conditions like prostate cancer and endometriosis.

Think of it as a switch that flips on briefly, then locks in the off position .

The deeper mechanism

Leuprolide is a synthetic nonapeptide (9-amino acid sequence: pyroGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt) that acts as a potent GnRH receptor agonist. Upon subcutaneous or intramuscular administration, leuprolide binds to GnRH receptors in the anterior pituitary with high affinity.

Initial agonistic activity causes rapid release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which increases testosterone production initially—this is termed 'flare.'

However, continuous exposure to leuprolide causes receptor desensitization and downregulation within 7-14 days, resulting in profound suppression of gonadotropin secretion.

This eliminates the LH stimulus for Leydig cell testosterone production (in males) or the FSH/LH stimulus for ovarian estrogen production (in females). Testosterone and estrogen levels typically drop 90-95% within 2-4 weeks.

The sustained suppression continues as long as the medication is administered.

Leuprolide's half-life is 2-3 hours for daily formulations, but depot formulations with fatty acid conjugation have extended half-lives of 2-5 weeks, enabling monthly to quarterly dosing through slow-release mechanisms.


What to expect

  1. initial_response

    What you might notice

    • May experience tumor flare (temporary worsening) if used for cancer;
    • hot flashes and decreased libido begin

    What's normal

    • Full integration of Leuprolide into physiological systems is established
    • Long-term Leuprolide response remains personalized to your physiology
    • Leuprolide tolerance is well-maintained with consistent dosing

    What's next

    • Maintain your established Leuprolide protocol for sustained benefits
    • Continue periodic monitoring to confirm Leuprolide efficacy
    • Review comprehensive Leuprolide response with your provider
  2. peak_effect

    What you might notice

    • Full testosterone suppression achieved;
    • endometriosis pain relief becomes noticeable;
    • tumor flare typically resolves

    What's normal

    • Leuprolide has achieved stable, long-term homeostatic integration
    • Sustained efficacy of Leuprolide remains consistent
    • Chronic Leuprolide effects remain stable and predictable

    What's next

    • Maintain your established Leuprolide protocol for sustained benefits
    • Continue periodic monitoring to confirm Leuprolide efficacy
    • Review comprehensive Leuprolide response with your provider
  3. long_term

    What you might notice

    • Sustained hormone suppression;
    • continued symptom relief;
    • bone density monitoring becomes important;
    • most side effects stabilize

    What's normal

    • Full therapeutic effects of Leuprolide are well-characterized at this point
    • Maintenance of Leuprolide's therapeutic effects is typical
    • Tolerance patterns with Leuprolide are generally stable over months

    What's next

    • Comprehensive assessment of Leuprolide efficacy should be conducted
    • Discuss long-term continuation, cycling, or protocol modifications
    • Continue regular monitoring of relevant biomarkers or symptoms

Signs it's working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to Leuprolide over time
  • Reduction in symptom frequency or severity

Signs it's working

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing results?

Common reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

464 registered studies, 58 still enrolling.

464registered studies
58recruiting now
157phase 3 or 4
108with published results

By phase

Phase 2

169

Phase 3

100

Phase 4

51

Phase 1

25

Phase 1/2

14

Phase 2/3

6

Early Phase 1

6

No phase

93

A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.

What kind of research

Gave the drug

424

Records only

40

About 87,747 people took part in the studies that actually administered Leuprolide. Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.


Most recent

  • NCT07782840 Phase 2Not Yet Recruiting40 enrolled

    QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy

    Hebei Medical University Fourth Hospital

  • NCT07340619 Phase 2Not Yet Recruiting51 enrolled

    Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.

    UNICANCER

  • NCT07596212 Phase 1/2Not Yet Recruiting100 enrolled

    BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

    University of Illinois at Chicago

See all 464 trials for Leuprolide

Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when Leuprolide is named as an intervention; studies that only mention it in passing are not.

Is leuprolide a steroid?

No, leuprolide is not a steroid. It's a peptide hormone that works on your hormone system to reduce testosterone and estrogen production. It's similar to a natural brain hormone called GnRH .

Can I get pregnant while taking leuprolide?

No. Leuprolide significantly reduces fertility and is dangerous if you become pregnant. Women should use effective birth control during treatment. Some fertility may return after stopping, but this needs to be discussed with your doctor .

How long do I need to take leuprolide?

That depends on your condition. For prostate cancer, it's usually long-term or continuous. For endometriosis or fibroids, treatment typically lasts 3-12 months. Your doctor will determine the right duration for you .

What's the difference between daily and depot leuprolide?

Daily leuprolide is a shot you give yourself every day. Depot forms are longer-lasting injections given monthly, quarterly, or even yearly by a doctor. Depot is more convenient but can't be adjusted as quickly. Most people prefer depot forms .

Why do men get hot flashes from leuprolide?

When testosterone drops suddenly, your body's temperature regulation gets confused. This is your brain responding to the hormonal change. Hot flashes usually improve over time or can be managed with medication if needed .

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for Leuprolide, on one page.

Leuprolide dosing protocol

Medical disclaimer

Leuprolide is FDA approved for the use described here. It is a prescription medication that should only be started, adjusted, or stopped under the supervision of a qualified healthcare provider. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 12, 2026

1 mg Once daily · onset 1-2 weeks
Open the Leuprolide calculatorLeuprolide calculator